LACTOLOGY FOUNDATION

Clinical Endocrinology of Human Adrenal Gland Disorders: Pathophysiology, Diagnostic Algorithms, and Therapeutic Strategies

Functional Anatomy and Histology of the Human Adrenal Gland

The human adrenal glands are paired retroperitoneal endocrine organs situated adjacent to the rostral poles of each kidney. In healthy adults, each gland weighs between $3\text{ g}$ and $5\text{ g}$ and measures approximately $5\text{ cm}$ in its maximum dimension. Morphologically, the gland resembles a flattened sphere with one invaginated surface, which yields a characteristic upside-down Y or V shape on cross-sectional computed tomography (CT) and magnetic resonance imaging (MRI). A key anatomical rule on cross-sectional imaging mandates that the thickness of an adrenal limb should not exceed the diameter of the ipsilateral diaphragmatic crus.

Histologically, the adrenal gland is partitioned into two embryologically and functionally distinct regions: an outer steroidogenic cortex of mesodermal origin and an inner neuroendocrine medulla derived from the neural crest. The adrenal cortex accounts for approximately $90\%$ of the total glandular volume and is subdivided into three concentric histological zones:

• Zona Glomerulosa: The thin, discontinuous outermost subcapsular layer represents approximately $5\%$ of cortical volume. Its constituent cells are arranged in rounded, glomerulus-like clusters. Standard histological processing extracts intracellular lipids from these cells, rendering them characteristically clear under microscopic examination. The zona glomerulosa functions as the exclusive site of mineralocorticoid synthesis, primarily aldosterone.
• Zona Fasciculata: The intermediate cortical layer constitutes roughly $70\%$ of total cortical volume. Its cells are arranged in long, parallel vertical cords resembling fascicles or the spine of a book. The zona fasciculata is dedicated to synthesizing glucocorticoids, predominantly hydrocortisone (cortisol).
• Zona Reticularis: The innermost cortical layer accounts for $10\%$ to $20\%$ of the mature gland's volume. It consists of intensely eosinophilic cells arranged in a branching, net-like network. In fetal life, an expanded counterpart known as the x-zone comprises the vast majority of the cortical volume. This fetal zone regresses during childhood and reappears at adrenarche—typically two to three years before the onset of puberty—to initiate the synthesis of adrenal androgen precursors, specifically dehydroepiandrosterone (DHEA), DHEA-sulfate (DHEA-S), and androstenedione.

The adrenal medulla accounts for the remaining $10\%$ of glandular mass. Its cellular architecture is analogous to a modified postganglionic sympathetic ganglion composed of chromaffin cells innervated directly by presynaptic sympathetic axons. Chromaffin cells lack dendrites and axons, secreting catecholamines directly into a rich capillary network.

Adrenocortical Endocrine Physiology and Regulatory Axes

Adrenocortical hormone synthesis depends on zone-specific enzymatic pathways regulated by distinct neuroendocrine and vascular feedback loops.

The Hypothalamic-Pituitary-Adrenal Axis and Cortisol Dynamics

Cortisol is synthesized from cholesterol within the zona fasciculata. Under unstressed baseline conditions, human cortisol is secreted at a physiological rate of $6.5\text{ mg/m}^2/\text{day}$. Cortisol secretion follows a robust circadian rhythm driven by the suprachiasmatic nucleus, peaking shortly after waking (06:00–08:00) and reaching a nadir near midnight.

The synthesis and release of cortisol are tightly governed by the hypothalamic-pituitary-adrenal (HPA) axis. Hypothalamic corticotropin-releasing hormone (CRH) stimulates the anterior pituitary gland to secrete adrenocorticotropic hormone (ACTH). ACTH binds to melanocortin-2 receptors ($MC2R$) on zona fasciculata cells, activating adenylate cyclase and increasing intracellular cyclic adenosine monophosphate (cAMP). This signal cascade upregulates the rate-limiting conversion of cholesterol to pregnenolone. Circulating cortisol exerts negative feedback control at both pituitary and hypothalamic levels: it rapidly suppresses ACTH secretion and more gradually inhibits CRH gene expression, maintaining physiological glucocorticoid homeostasis.

The Renin-Angiotensin-Aldosterone System and Mineralocorticoid Regulation

Aldosterone synthesis in the zona glomerulosa is governed primarily by the renin-angiotensin-aldosterone system (RAAS) and ambient serum potassium levels, functioning independently of pituitary ACTH control under physiological conditions. Juxtaglomerular cells in the renal afferent arterioles act as baroreceptors that monitor intravascular volume and perfusion pressure. A drop in vascular volume or renal arterial pressure triggers renin release into the circulation. Renin cleaves liver-derived angiotensinogen to yield angiotensin I, which is subsequently converted to angiotensin II by angiotensin-converting enzyme (ACE), predominantly within the pulmonary circulation.

Angiotensin II binds to type 1 angiotensin ($AT_1$) receptors in the zona glomerulosa, stimulating aldosterone synthase ($CYP11B2$) expression and aldosterone secretion. Aldosterone acts on epithelial sodium channels ($ENaC$) and $Na^+/K^+$-ATPase pumps within the thick ascending limb of the loop of Henle and the distal nephron to promote renal sodium retention, expand intravascular volume, and facilitate potassium and hydrogen ion excretion. The resulting intravascular expansion suppresses juxtaglomerular renin release, completing the feedback loop. In healthy individuals consuming a standard sodium diet, aldosterone is secreted at a rate of approximately $100\text{ }\mu\text{g/day}$.

Adrenal Androgens and Medullary Catecholamine Dynamics

Adrenal androgen precursors—DHEA, DHEA-S, and androstenedione—are secreted by the zona reticularis. Although these precursors possess weak intrinsic androgenic activity, peripheral tissues convert them into potent testosterone and dihydrotestosterone (DHT). Adrenal androgen secretion is driven by ACTH, but lacks a direct negative feedback loop.

The adrenal medulla synthesizes catecholamines, comprising roughly $80\%$ epinephrine and $20\%$ norepinephrine. Chromaffin cell catecholamine production depends on the unique vascular anatomy of the adrenal gland. Centripetal blood flow drains through the cortical capillary bed into medullary sinusoids, exposing chromaffin cells to high intra-adrenal cortisol concentrations. Cortisol induces phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts norepinephrine into epinephrine. Catecholamine release is triggered by preganglionic sympathetic stimulation during acute physical or psychological stress and operates without direct classical feedback mechanisms.

Disorders of Glucocorticoid Excess: Cushing's Syndrome

Cushing's syndrome comprises the clinical features resulting from prolonged exposure to systemic glucocorticoid levels exceeding the normal production rate of $6.5\text{ mg/m}^2/\text{day}$. Harvey Cushing first described the disorder in 1912.

Etiology and Pathophysiological Classification

Hypercortisolism is classified into ACTH-dependent and ACTH-independent etiologies based on circulating ACTH levels. Exogenous glucocorticoid therapy represents the most common cause of Cushingoid features overall. Among endogenous cases, ACTH-dependent hypercortisolism accounts for approximately $90\%$ of presentations.

Clinical Presentation and Risk Stratification

The clinical signs of Cushing's syndrome reflect widespread glucocorticoid action across metabolic, cardiovascular, skeletal, and cutaneous tissues. Features vary in their diagnostic utility:

• Highly Discriminatory Features: Facial plethora (sensitivity $82\%$, specificity $69\%$), proximal muscle weakness or myopathy (sensitivity $65\%$, specificity $93\%$), reddish-purple abdominal striae $> 1\text{ cm}$ wide (sensitivity $40\%$, specificity $78\%$), and easy bruising with thin skin.
• Less Discriminatory Overlapping Features: Truncal/central obesity (sensitivity $90\%$, specificity $71\%$), glucose intolerance or type 2 diabetes mellitus (sensitivity $88\%$, specificity $23\%$), systemic hypertension, osteopenia or vertebral osteoporosis (sensitivity $64\%$, specificity $97\%$), dorsocervical fat pad ("buffalo hump"), hirsutism, oligomenorrhea, and neuropsychiatric disturbances.

Loriaux categorizes Cushing's syndrome into three distinct biochemical-clinical phenotypes based on the relationship between urinary free cortisol (UFC) excretion and clinical severity:

1. Classic Cushing's Syndrome: Marked clinical features combined with significantly elevated 24-hour UFC levels.
2. Atypical Cushing's Syndrome: Prominent clinical signs accompanied by low or normal UFC excretion, most frequently seen in factitious or exogenous steroid administration.
3. Anorexia-Associated Cushing's Syndrome: Substantially elevated 24-hour UFC levels with minimal clinical manifestations, typically observed in rapidly progressing ectopic ACTH-secreting tumors (e.g., small cell lung carcinoma) where somatic wasting limits tissue Cushingoid changes.

Diagnostic and Localization Protocols

Biochemical confirmation of hypercortisolism must precede radiological imaging, and exogenous steroid use must be ruled out before testing.

SUSPECTED CUSHING'S SYNDROME

  │

  ├── Exclude Exogenous Glucocorticoid Exposure

  │

  ├── First-Line Screening (Perform 1 or 2 tests):

  │     ├── 24-Hour Urinary Free Cortisol (UFC) [>100 µg/day]

  │     ├── 1-mg Overnight Dexamethasone Suppression Test [Serum Cortisol >1.8 µg/dL]

  │     └── Late-Night Salivary Cortisol [>145 ng/dL / >4 nmol/L]

  │

  ├── Confirmed Hypercortisolism -> Measure Plasma ACTH

  │     │

  │     ├── ACTH < 10 pg/mL (ACTH-Independent)

  │     │     └── Adrenal CT / MRI Imaging

  │     │           ├── Solitary Mass -> Adrenalectomy

  │     │           └── Bilateral Nodules -> Primary Pigmented Nodular Dysplasia

  │     │

  │     └── ACTH >= 10 pg/mL (ACTH-Dependent)

  │           └── Pituitary Contrast MRI

  │                 ├── Microadenoma Identified -> Transsphenoidal Surgery

  │                 └── Normal / Indeterminate MRI -> Inferior Petrosal Sinus Sampling (IPSS)

  │                       ├── Central-to-Peripheral ACTH Ratio > 3 (post-CRH) -> Pituitary

  │                       └── Central-to-Peripheral ACTH Ratio < 3 -> Ectopic ACTH Search (Thoracic CT/MRI)

Initial Screening Tests

Establishing autonomous cortisol excess requires at least one abnormal result from the following validated screening tests:

• 24-Hour Urinary Free Cortisol (UFC): Measures un-bound circulating cortisol filtered by the kidneys. Excretion exceeding the upper limit of normal ($> 100\text{ }\mu\text{g/day}$) on two separate collections indicates hypercortisolism. Levels exceeding $300\text{ }\mu\text{g/day}$ confirm Cushing's syndrome without requiring additional screening tests.
• 1-mg Overnight Dexamethasone Suppression Test (DST): Oral administration of $1\text{ mg}$ dexamethasone at 23:00, followed by serum cortisol measurement at 08:00 the next morning. A post-dexamethasone serum cortisol level $> 1.8\text{ }\mu\text{g/dL}$ ($50\text{ nmol/L}$) indicates autonomous cortisol secretion.
• Late-Night Salivary Cortisol: Evaluates loss of the physiological diurnal cortisol nadir. Salivary cortisol concentrations $> 145\text{ ng/dL}$ ($4\text{ nmol/L}$) on two consecutive late-night samples demonstrate high sensitivity and specificity.

Differential Diagnosis and Etiological Localization

Once hypercortisolism is established, measuring circulating plasma ACTH differentiates ACTH-dependent from ACTH-independent causes:

• Plasma ACTH $< 10\text{ pg/mL}$: Confirms ACTH-independent Cushing's syndrome. If random ACTH levels are equivocal, a CRH challenge test ($1\text{ }\mu\text{g/kg}$ IV bolus) is performed; a persistent post-CRH ACTH level $< 10\text{ pg/mL}$ confirms a primary adrenal etiology. Adrenal CT or MRI should be obtained to distinguish a benign solitary adenoma from adrenocortical carcinoma or bilateral dysplasia.
• Plasma ACTH $\ge 10\text{ pg/mL}$: Indicates ACTH-dependent Cushing's syndrome. Contrast-enhanced pituitary MRI is the initial imaging modality. Because up to $50\%$ of pituitary ACTH-secreting microadenomas measure under $5\text{ mm}$ and remain undetected on MRI, a normal scan mandates bilateral inferior petrosal sinus sampling (IPSS).
• Inferior Petrosal Sinus Sampling (IPSS): Microcatheters are guided into both inferior petrosal sinuses and a peripheral vein simultaneously to measure ACTH before and after IV CRH administration. A central-to-peripheral ACTH gradient $> 2$ at baseline or $> 3$ following CRH stimulation confirms pituitary Cushing's disease. A gradient $< 3$ points to an ectopic ACTH-secreting tumor, prompting high-resolution thoracic CT and MRI to localize bronchial carcinoids or neuroendocrine tumors.

Therapeutic Management

Surgical resection of the underlying tumor is the primary treatment for all forms of endogenous Cushing's syndrome.

Transsphenoidal selective adenomectomy is the procedure of choice for pituitary Cushing's disease. Unilateral laparoscopic adrenalectomy is indicated for benign cortisol-secreting adrenal adenomas, whereas open radical adrenalectomy with clear margins is required for adrenocortical carcinoma. Bilateral adrenalectomy provides definitive control when an ectopic ACTH source cannot be localized or resected.

Successful resection of an ACTH- or cortisol-secreting tumor causes transient postoperative adrenal insufficiency by suppressing the non-tumorous HPA axis. Serum cortisol measured on the morning of post-operative day 1 guides management:

• Morning Cortisol $< 5\text{ }\mu\text{g/dL}$: Confirms surgical cure. The patient requires temporary oral hydrocortisone replacement ($12\text{ mg/m}^2/\text{day}$ as a single dose with breakfast) until the HPA axis recovers. HPA axis recovery is reassessed at 3-month intervals using a cosyntropin stimulation test. Hydrocortisone can be safely discontinued once post-stimulation peak cortisol reaches $\ge 20\text{ }\mu\text{g/dL}$.
• Morning Cortisol $> 20\text{ }\mu\text{g/dL}$: Indicates surgical failure and persistent hypercortisolism.
• Bilateral Adrenalectomy: Requires lifelong replacement of both glucocorticoids (hydrocortisone $12–15\text{ mg/m}^2/\text{day}$) and mineralocorticoids (fludrocortisone $0.1\text{ mg/day}$).

Inoperable, recurrent, or occult cases can be managed pharmacologically with adrenal steroidogenesis inhibitors. Ketoconazole inhibits $CYP17A1$ and $CYP11A1$ activity, reducing cortisol synthesis. Mitotane ($o,p'-DDD$) exerts adrenolytic effects and is used primarily in advanced adrenocortical carcinoma.

Primary and Secondary Adrenal Insufficiency

Adrenal insufficiency (Addison's disease) results from direct structural destruction of the adrenal cortex (primary) or impaired pituitary ACTH secretion (secondary).

Etiology and Pathophysiology

Primary adrenal insufficiency involves destruction of all three cortical zones, leading to combined glucocorticoid, mineralocorticoid, and adrenal androgen deficiencies. Autoimmune adrenalitis accounts for approximately $70\%$ of cases in industrialized nations, whereas infectious etiologies—predominantly tuberculosis—cause roughly $20\%$ of cases worldwide. Additional primary causes include fungal infections, bilateral adrenal hemorrhage, adrenoleukodystrophy, metastatic disease, and congenital ACTH unresponsiveness.

Secondary adrenal insufficiency stems from deficient pituitary ACTH release, leading to secondary atrophy of the zonae fasciculata and reticularis. Mineralocorticoid secretion by the zona glomerulosa remains largely intact because it is governed primarily by the RAAS. Prolonged therapeutic glucocorticoid administration is the most common cause of secondary adrenal insufficiency, accounting for over $90\%$ of cases. Exogenous steroids suppress hypothalamic CRH and pituitary ACTH, and recovery of normal HPA axis function after steroid withdrawal may take a year or longer. Less common secondary causes include pituitary adenomas, craniopharyngiomas, lymphocytic hypophysitis, head trauma, and surgical hypophysectomy.

Clinical Manifestations

Chronic adrenal insufficiency develops insidiously. Symptoms include progressive fatigue, anorexia, weight loss, generalized weakness, nausea, abdominal pain, and orthostatic hypotension. Cutaneous and mucosal hyperpigmentation—most prominent on sun-exposed areas, palmar creases, and surgical scars—is a hallmark feature unique to primary adrenal insufficiency. It results from compensatory pituitary pro-opiomelanocortin (POMC) synthesis, which yields high circulating levels of ACTH and $\alpha$-melanocyte-stimulating hormone ($\alpha$-MSH). Hyponatremia and hyperkalemia occur in primary adrenal insufficiency due to mineralocorticoid deficiency, whereas secondary adrenal insufficiency typically presents with isolated dilutional hyponatremia driven by unsuppressed vasopressin release, without hyperkalemia.

Acute adrenal crisis is a medical emergency characterized by sudden vascular collapse and distributive shock refractory to volume resuscitation and vasopressors. Features include high fever, severe vomiting, acute abdominal pain, confusion, and profound hypoglycemia.

Diagnostic Protocols

Adrenal insufficiency should be suspected clinically and confirmed biochemically using dynamic testing.

SUSPECTED ADRENAL INSUFFICIENCY

  │

  ├── Chronic Presentation -> Cosyntropin Stimulation Test (250 µg IV)

  │     ├── Peak Cortisol > 20 µg/dL -> Adrenal Insufficiency Excluded

  │     └── Peak Cortisol < 20 µg/dL -> Adrenal Insufficiency Confirmed

  │           │

  │           ├── Plasma ACTH > Upper Limit -> Primary Adrenal Insufficiency

  │           │     └── Perform Adrenal CT / MRI Imaging

  │           │           ├── Enlarged Glands -> Infection, Hemorrhage, Metastasis

  │           │           └── Small / Normal Glands -> Autoimmune Adrenalitis

  │           │

  │           └── Plasma ACTH Low / Normal -> Secondary Adrenal Insufficiency

  │                 └── Assess for Exogenous Steroid Use / Pituitary MRI

  │

  └── Acute Crisis Presentation -> Immediate Random Cortisol + IV Hydrocortisone 100 mg

        (Do NOT delay resuscitation for diagnostic testing)

Cosyntropin Stimulation Test

The $250\text{ }\mu\text{g}$ cosyntropin (synthetic $\text{ACTH}_{1-24}$) stimulation test is the standard diagnostic evaluation for chronic adrenal insufficiency:

1. Cosyntropin ($250\text{ }\mu\text{g}$) is administered as an intravenous or intramuscular bolus.
2. Plasma cortisol is measured at 45 and 60 minutes post-injection.
3. A peak plasma cortisol level $> 20\text{ }\mu\text{g/dL}$ excludes primary adrenal insufficiency.
4. A peak plasma cortisol level $< 20\text{ }\mu\text{g/dL}$ confirms adrenal insufficiency, requiring replacement therapy while the underlying etiology is investigated.

Etiological Differentiation

Measuring baseline plasma ACTH differentiates primary from secondary causes:

• Elevated Baseline ACTH: Confirms primary adrenal insufficiency. Cross-sectional CT or MRI imaging should be performed. Infectious, infiltrative, hemorrhagic, or malignant etiologies characteristically produce bilateral adrenal enlargement, whereas autoimmune destruction presents with small or normal-sized glands.
• Low or Normal Baseline ACTH: Confirms secondary adrenal insufficiency. If exogenous steroid suppression is ruled out, contrast-enhanced MRI of the pituitary and hypothalamus is indicated.

In acute adrenal crisis, treatment must not be delayed for diagnostic procedures. A random plasma cortisol level $< 20\text{ }\mu\text{g/dL}$ in a severely ill patient in distributive shock supports the diagnosis. Hypoalbuminemia reduces total plasma cortisol concentrations without altering free cortisol levels, which should be considered when interpreting results in critically ill patients.

Replacement Protocols and Stress-Dosing Dynamics

Therapy aims to replace missing glucocorticoids and mineralocorticoids to match physiological requirements.

• Maintenance Therapy: Primary adrenal insufficiency is managed with oral hydrocortisone at $12\text{ mg/m}^2/\text{day}$ to $15\text{ mg/m}^2/\text{day}$, given as a single morning dose with breakfast (or split into two-thirds in the morning and one-third in the early afternoon). This dose exceeds normal endogenous secretion ($6.5\text{ mg/m}^2/\text{day}$) to compensate for hepatic first-pass metabolism. Mineralocorticoid replacement requires oral fludrocortisone at $0.1\text{ mg/day}$. Secondary adrenal insufficiency requires hydrocortisone replacement alone, as mineralocorticoid secretion is preserved.
• Stress-Dosing Adjustments: During minor to moderate physical stress (e.g., febrile illness $> 38.5^\circ\text{C}$ or dental procedures), the routine hydrocortisone dose should be doubled for two to three days. During major surgical procedures or severe trauma, intravenous hydrocortisone is administered at $100\text{ mg}$ every 6 hours ($400\text{ mg/day}$) from induction until 48–72 hours postoperatively, after which the dose is tapered to baseline. Routine psychological stress does not warrant hydrocortisone escalation. All patients must wear a medical-alert bracelet and carry an emergency corticosteroid injection kit.

Mineralocorticoid Disorders: Primary and Secondary Hyperaldosteronism and Hypoaldosteronism

Disorders of mineralocorticoid excess or deficiency impair systemic blood pressure, sodium balance, and serum potassium levels.

Primary Hyperaldosteronism (Conn's Syndrome)

Primary hyperaldosteronism is characterized by autonomous aldosterone secretion independent of renin control. It accounts for approximately $2\%$ to $10\%$ of hypertension cases.

Primary Etiologies

1. Aldosterone-Producing Adenoma (APA): Solitary, benign zona glomerulosa adenomas (typically $< 2.5\text{ cm}$) cause roughly $60\%$ of primary hyperaldosteronism cases.
2. Idiopathic Bilateral Adrenal Hyperplasia (IAH): Bilateral diffuse or nodular zona glomerulosa hyperplasia accounts for $35\%$ to $40\%$ of cases.
3. Glucocorticoid-Remediable Aldosteronism (GRA / Familial Hyperaldosteronism Type 1): A rare autosomal dominant disorder caused by a chimeric gene mutation fusing the promoter of 11$\beta$-hydroxylase ($CYP11B1$) to the coding region of aldosterone synthase ($CYP11B2$). This mutation places aldosterone synthesis under direct ACTH control.

Diagnostic Evaluation and Subtype Localization

The classic triad comprises hypertension, hypokalemia, and metabolic alkalosis.

Unilateral laparoscopic adrenalectomy cures hypertension and hypokalemia in approximately $75\%$ of patients with an aldosterone-producing adenoma. Patients with idiopathic bilateral hyperplasia are managed medically with mineralocorticoid receptor antagonists (spironolactone $100–400\text{ mg/day}$ or selective eplerenone), alongside ACE inhibitors or calcium channel blockers.

Secondary Hyperaldosteronism

Secondary hyperaldosteronism results from extra-adrenal activation of the RAAS, characteristically presenting with elevations in both plasma renin activity and aldosterone levels:

• Hypertensive Forms: Renovascular disease (renal artery stenosis), malignant hypertension, or rare renin-secreting juxtaglomerular cell tumors (reninomas).
• Non-Hypertensive Forms: Reduced effective circulating arterial volume caused by congestive heart failure, hepatic cirrhosis with ascites, nephrotic syndrome, or Bartter syndrome. Bartter syndrome stems from autosomal recessive transport defects in the thick ascending limb of Henle's loop, producing salt wasting, hyperreninemic hyperaldosteronism, hypokalemic alkalosis, and normal blood pressure.

Hypoaldosteronism and Mineralocorticoid Resistance

Hypoaldosteronism causes urinary sodium wasting, hyperkalemia, metabolic acidosis, and orthostatic hypotension:

• Primary Hypoaldosteronism: Caused by primary adrenal failure or rare congenital mutations in aldosterone biosynthesis, such as Corticosterone Methyl Oxidase type I or II (CMO-I/CMO-II) deficiency. Plasma renin activity is elevated. Treatment includes a high-sodium diet and oral fludrocortisone ($0.1-0.2\text{ mg/day}$).
• Secondary Hypoaldosteronism (Hyporeninemic Hypoaldosteronism / Type 4 RTA): The most common form of isolated mineralocorticoid deficiency, frequently presenting in older adults with diabetic nephropathy or chronic tubulointerstitial disease. Juxtaglomerular damage leads to low renin and aldosterone levels. Management includes low-potassium diet, loop diuretics, and oral fludrocortisone ($0.1–0.2\text{ mg/day}$).
• Pseudohypoaldosteronism (Target-Organ Resistance): Type I involves inactivating mutations in the mineralocorticoid receptor ($NR3C2$) or $ENaC$ channels, causing severe infantile salt wasting treated with high sodium intake ($10–40\text{ mEq/kg/day}$). Type II (Gordon's syndrome) stems from $WNK1$ or $WNK4$ kinase mutations, causing hyperkalemia, metabolic acidosis, and volume-expansion hypertension, which responds to thiazide diuretics.

Congenital Adrenal Hyperplasia

Congenital Adrenal Hyperplasia (CAH) comprises autosomal recessive enzymatic defects in adrenocortical cortisol biosynthesis.

Pathophysiology of 21-Hydroxylase Deficiency

Mutations in $CYP21A2$ (21-hydroxylase) account for over $90\%$ of CAH cases. Impaired 21-hydroxylase activity reduces conversion of progesterone to 11-deoxycorticosterone (DOC) and 17-hydroxyprogesterone (17-OHP) to 11-deoxycortisol. Decreased cortisol synthesis leads to loss of negative feedback and persistent pituitary ACTH hypersecretion. Sustained ACTH stimulation drives bilateral adrenal cortical hyperplasia and shunts accumulated precursor steroids (predominantly 17-OHP) into the intact adrenal androgen pathway, leading to prenatal and postnatal androgen excess.

Clinical Phenotypes and Diagnostic Evaluation

CAH presents along a spectrum of clinical severity based on residual 21-hydroxylase activity:

• Classic Salt-Wasting CAH: Complete loss of enzymatic activity ($< 1\%$) causes severe cortisol and aldosterone deficiency. Neonates present at 1 to 3 weeks of life with hyponatremic, hyperkalemic salt-wasting crisis, dehydration, and circulatory collapse. Affected female infants exhibit genital ambiguity (female pseudohermaphroditism) due to exposure to high intrauterine androgen levels.
• Classic Simple Virilizing CAH: Residual enzyme activity ($1–2\%$) maintains sufficient mineralocorticoid synthesis to preserve sodium balance. However, prenatal androgen excess causes ambiguous genitalia in newborn females and precocious pseudopuberty in males.
• Non-Classic CAH (NC-CAH / Late-Onset): Partial enzyme deficiency ($20–70\%$ residual activity) presents in adolescence or adulthood with oligomenorrhea, hirsutism, acne, and subfertility, clinically resembling polycystic ovary syndrome (PCOS).

SUSPECTED CONGENITAL ADRENAL HYPERPASIA (21-Hydroxylase Deficiency)

  │

  ├── Neonatal Screening -> Dried Blood Spot 17-OHP Assay

  │     └── Positive Screen -> Confirm with Serum LC-MS/MS 17-OHP & Electrolytes

  │

  └── Adolescent / Adult Presentation (Symptomatic NC-CAH)

        │

        └── Early Morning (08:00 AM) Baseline Serum 17-OHP

              ├── < 200 ng/dL -> Normal (CAH Excluded)

              ├── > 1000 ng/dL -> Diagnostic of 21-Hydroxylase Deficiency

              └── 200–1000 ng/dL (Borderline) -> Cosyntropin Stimulation Test (250 µg IV)

                    ├── Post-Stimulation 17-OHP < 340 ng/dL -> Normal

                    └── Post-Stimulation 17-OHP >= 1000 ng/dL -> Confirms NC-CAH

Diagnosis relies on measuring early morning baseline 17-OHP or performing a $250\text{ }\mu\text{g}$ cosyntropin stimulation test. In healthy individuals, post-stimulation 17-OHP remains $< 340\text{ ng/dL}$ ($10\text{ nmol/L}$), whereas values $\ge 1000\text{ ng/dL}$ ($30\text{ nmol/L}$) confirm 21-hydroxylase deficiency.

Therapeutic Strategy and Monitoring

Treatment requires physiological replacement with hydrocortisone ($12–15\text{ mg/m}^2/\text{day}$) and fludrocortisone ($0.1–0.2\text{ mg/day}$) to suppress excessive ACTH release and lower adrenal androgen production. Biochemical monitoring aims to maintain morning 17-OHP levels between $400\text{ ng/dL}$ and $600\text{ ng/dL}$ ($12–18\text{ nmol/L}$). Complete normalization of 17-OHP is avoided because it requires supraphysiological glucocorticoid doses that cause iatrogenic Cushing's syndrome and growth retardation. Inadequately controlled ACTH hypersecretion can stimulate ectopic adrenal rest tissue, leading to Testicular Adrenal Rest Tumors (TARTs) in males, which cause intratesticular pain, duct obstruction, and infertility.

Adrenomedullary Pathology, Incidentalomas, and Adrenocortical Carcinoma

Pheochromocytoma

Pheochromocytomas are catecholamine-secreting neuroendocrine tumors derived from chromaffin cells of the adrenal medulla. Approximately $90\%$ arise within the adrenal medulla, while $10\%$ develop in extra-adrenal sympathetic paraganglia (paragangliomas). Up to $40\%$ of patients harbor germline susceptibility mutations, including RET (MEN2A/2B), VHL (von Hippel-Lindau), NF1 (Neurofibromatosis type 1), and SDHB/D (succinate dehydrogenase subunits).

Systemic hypertension—either persistent ($50\%$) or paroxysmal ($50\%$)—is the main clinical presentation. Paroxysmal release causes a classic triad: severe episodic headache, diaphoresis, and tachycardia. The presence of all three features in a hypertensive patient demonstrates $> 90\%$ diagnostic specificity.

Diagnosis requires demonstrating elevated catecholamine metabolites. Measuring plasma free metanephrines or 24-hour urinary fractionated metanephrines provides high diagnostic sensitivity. Excretion of total urinary catecholamines $> 100\text{ }\mu\text{g/day}$ or total metanephrines $> 1.3\text{ mg/day}$ supports the diagnosis. Cross-sectional MRI typically reveals $T_2$-weighted hyperintensity ("lightbulb sign"), while non-contrast CT shows density $> 10\text{ HU}$. Functional scintigraphy ($^{123}\text{I-MIBG}$ or $^{68}\text{Ga-DOTATATE}$ PET/CT) localizes extra-adrenal or metastatic disease.

Complete $\alpha$-adrenergic blockade is mandatory prior to surgery to prevent intraoperative hypertensive crisis. Phenoxybenzamine is initiated 7 to 14 days preoperatively at $10\text{ mg}$ twice daily and titrated up to $\ge 1\text{ mg/kg/day}$. Beta-blockers (e.g., propranolol) may be added only after establishing effective $\alpha$-blockade; administering $\beta$-blockers first leaves $\alpha_1$-mediated vasoconstriction unopposed, precipitating severe hypertensive crisis.

Adrenal Incidentalomas

An adrenal incidentaloma is an unsuspected mass $\ge 1\text{ cm}$ detected on abdominal imaging performed for unrelated reasons. Incidentalomas are identified in roughly $4\%$ of abdominal CT scans. Evaluation must address hormonal functionality and malignant potential:

Asymptomatic, non-functional incidentalomas with benign radiological features ($< 10\text{ HU}$, rapid contrast washout, diameter $< 4\text{ cm}$) do not require surgery. Resection is indicated for functional lesions, subclinical pheochromocytomas, tumors with delayed contrast washout, or masses $> 6\text{ cm}$. Fine-needle aspiration biopsy is contraindicated unless pheochromocytoma is ruled out, and is used primarily to confirm suspected metastases from a known extra-adrenal primary malignancy.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy with an annual incidence of 1 in 600,000 (~500 new cases annually in the United States). ACC usually presents as a large unilateral mass ($> 6\text{ cm}$) associated with mixed hormone excess. The combination of Cushing's syndrome and rapid virilization in a female, or feminization in a male, strongly suggests ACC. Neoplastic adrenocortical cells lose steroidogenic efficiency during dedifferentiation; consequently, a substantial tumor mass must accumulate to produce clinically evident hormone hypersecretion.

Complete surgical resection with negative margins ($R_0$) offers the best chance for cure. Debulking procedures can reduce tumor burden and help control severe hormone excess. Pharmacotherapy includes mitotane ($o,p'-DDD$), an adrenolytic agent administered at doses $> 2\text{ g/day}$, alongside steroidogenesis inhibitors such as ketoconazole. Median survival without surgery is several months, whereas aggressive surgical resection can extend median survival to approximately 48 months.

Conclusions

Disorders of the human adrenal glands encompass a spectrum of clinical conditions ranging from functional hypersecretory states to primary hormonal deficiencies and malignant neoplasms. Diagnostic evaluation requires systematic integration of baseline hormone measurements, dynamic endocrine suppression and stimulation testing, and high-resolution imaging modalities. Differentiating primary from secondary adrenal pathology relies on paired pituitary and adrenocortical hormone assays, such as plasma ACTH, urinary free cortisol, plasma renin activity, and serum aldosterone.

Establishing precise localization through specialized procedures—such as inferior petrosal sinus sampling and adrenal venous sampling—helps guide targeted surgical intervention. Therapeutic strategies aim to achieve complete tumor resection where appropriate, while restoring physiological hormone balance through carefully monitored replacement protocols or targeted pharmacotherapy.